Impact of mRNA chemistry and manufacturing process on innate immune activation

Nelson, Jennifer, Sorensen, Elizabeth W., Mintri, Shrutika, Rabideau, Amy E., Zheng, Wei, Besin, Gilles, Khatwani, Nikhil, Su, Stephen V. +5 more·2020·Science Advances
DOI 10.1126/sciadv.aaz6893

Cited by (353)

Items 301–353 of 353

  1. Improving the fidelity of uridine analog incorporation during in vitro transcription
    Tien-Hao Chen, Vladimir Potapov, Nan Dai, Jennifer L. Ong, Bijoyita Roy · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  2. Condon Optimization: Codon Optimization of Therapeutic Proteins: Suggested Criteria for Increased Efficacy and Safety
    Vincent P. Mauro · 2022 · Springer eBooks
  3. Lipid Nanoparticles to Harness the Therapeutic Potential of mRNA for Cancer Treatment
    Maria L. Guevara, Francesca Persano, Stefano Persano · 2022 · RNA technologies
  4. Synthetic mRNA Gene Therapies and Hepatotropic Non-viral Vectors for the Treatment of Chronic HBV Infections
    Dylan Kairuz, Prashika Singh, Tiffany S. Smith, Patrick B. Arbuthnot, Abdullah Ely, Kristie M. Bloom · 2022 · RNA technologies
  5. Tantangan dan Perkembangan Vaksin HIV (Human Immunodeficiency Virus)
    Wil Hel Minah, Rahma Ziska, Mohamad Isronijaya · 2022 · Jurnal Health Sains
  6. Studying the effect of double-stranded RNA upon activity of mouse splenocytes using flow cytometry
    E. S. Tsyplenkova, E. A. Vyazovaya, Е. Д. Даниленко · 2022 · Medical Immunology (Russia)
  7. Messenger RNA Nanovaccine in Cancer Immunotherapy
    Mengyun Li, Hongxia Zhang · 2022 · Springer eBooks
  8. 5‐Ethynyluridine: A Bio‐orthogonal Uridine Variant for mRNA‐Based Therapies and Vaccines
    Sjors Maassen, Britt A. Coenen, Sarah-Luisa Dülk, Martijn van der Werff, Harry M. Warner, Fabio Spada, Thomas Frischmuth, Danny Incarnato, Geert van den Bogaart · 2023 · ChemBioChem
  9. Transcriptome-wide detection and characterization of pseudouridine mRNA modifications across diverse human cell lines
    Caroline A. McCormick · 2024
  10. RNA Temelli Terapötik Yaklaşımlar
    İsmail Korkmaz, Serdal Arslan · 2024 · Uludağ Üniversitesi Tıp Fakültesi Dergisi
  11. mRNA Technologies Danger
    M. V. Supotnitskiy · 2024 · Journal of NBC Protection Corps
  12. RNA as a Mediator of Host-Fungal Pathogenesis
    Alexander Bruch, Matthew G. Blango · 2024 · The mycota
  13. Maternal transfer of mRNA LNP-derived, pathogen-specific, monoclonal IgG to suckling mice
    Jennifer E. Doering, Yetunde Adewunmi, Cailin E. Deal, Obadiah J. Plante, Andrea Carfı́, Nicholas John Mantis · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  14. Reconfiguration of tumor cells with LCOR transcription factor mRNA nanotherapy to enhance immunotherapy efficacy
    Gabriel Serra-Mir, Elena Haro-Martínez, Chiara Cannatá, José Ángel Palomeque, Sandra Blasco-Benito, Anna López‐Plana, María Sanz‐Flores, Marc Sabartés, Cristina Fornaguera, Toni Celià-Terrassa · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  15. Residual DNAs as adjuvants in existing mRNA vaccines - a multidisciplinary analysis
    Siguna Mueller · 2025
  16. Residual DNAs as adjuvants in existing mRNA vaccines - a multidisciplinary analysis
    Siguna Mueller · 2025
  17. Lateral Flow Immunoassay for Rapid and Sensitive Detection of dsRNA Contaminants in In Vitro-Transcribed mRNA Products
    Dengwang Luo, Daming Wang, Yuhong Cao · 2025 · Methods in molecular biology
  18. Defective Host Immunity in a Mouse Hindlimb Ischemia Model Attenuates the Blood Flow Recovery Promoted by an mRNA/LNP Formulation
    Hanae Toyonaga, Lei Cheng, Hirotsugu Tanaka · 2025 · Molecular Pharmaceutics
  19. Therapeutic potential of exogenous mRNA encoding recombinant antibodies against viral pathogens
    Sergey A. Klotchenko, Marina A. Plotnikova · 2025 · Medical academic journal
  20. mRNA-based vaccines: Rational antigen design, delivery optimization, and immune modulation
    Shengbin Liu, Haixing Shi, Danni Dai, Tingchen Tian, Xing Duan, Ju Sun, Weitong Xu, Xiaoling Yin, Yongmei Xie, Xiangrong Song · 2025 · Chinese Chemical Letters
  21. Structural analysis of uridine modifications in solved RNA structures
    Sebastian J. Arteaga, Brent M. Znosko · 2025 · NAR Genomics and Bioinformatics
  22. Direct Cytoplasmic Transcription and Trimeric RBD Design Synergize to Enhance DNA Vaccine Potency Against SARS-CoV-2
    Yunju Nam, Sang Chul Shin, Sang Won Cho, Hyung Jun Ahn · 2026 · Pharmaceutics
  23. CRISPR as a therapeutic tool for inherited retinal degenerations: Advances, challenges, and future directions
    Eglė Galdikaitė, Raulas Krušnauskas, Emiline Henderson, Kinga M. Bujakowska · 2026 · Molecular Aspects of Medicine
  24. Robust CD8+ T cell responses induced by an mRNA-LNP vaccine encoding rat HER2 extracellular domain confer prophylactic tumor protection
    K. Li, Xiaoya Li, Cong Zhang, Suli Dai, Lei Li, Jun Wang, Hongtao Zhang, Li Zhao · 2026 · Frontiers in Immunology
  25. Optimising a mRNA Vaccine platform against HIV-1 : from the in vitro transcription design to envelope protein expression
    Sergio Linares-Fernández · 2021
  26. Caractérisation de la réponse lymphocytaire B mémoire contre le SARS-CoV-2 après infection ou vaccination
    Aurélien Sokal · 2022 · theses.fr (ABES)
  27. Resolving the Unresolvable: Nanopore Sequencing as a Comprehensive Quality Control Platform for Gene Therapy Vectors
    Yan Xu, Xiao-Bing Zhang, Jian-Ping Zhang · 2026 · Human Gene Therapy
  28. Circular RNA vaccine performance is determined by RNA quality and epitranscriptomic tuning rather than innate activation
    Abby L. Martin, Jessica Cotterell, Kaitlin H. Buick, Thomas W. Bird, Joanna Kuang, Olga Rose Palmer, Ngarangi C. Mason, Lydia G. White, Sarah L. Draper, Amy J. Foster et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  29. Tailored HER2 ECD mRNA-LNP vaccines boost CD8+ T cell-mediated antitumor immunity for HER2-positive tumor suppression
    Kexin Li, Zilin Ma, Xiaoya Li, Xiuping Chi, Ying Zhang, Cong Zhang, Wen Li, Mingyu Cui, Wei Qi, Yating Zhao et al. · 2026 · Drug Resistance Updates
  30. Circular RNA-based therapeutic vaccine elicits potent antigen-specific antitumor immunity and remodels tumor microenvironment in lung cancer
    Shaoyi Chen, Lin Weng, Xu Liu, Zewen Sun, Jing Bai, Jun Wang, Kezhong Chen, Mantang Qiu · 2026 · Cancer Letters
  31. Engineering the blood: Lipid nanoparticle platforms for ex vivo immune and hematopoietic cell therapies
    Yongjoo Byeon, Nuoya Peng, Eun Bee Oh, Eunbin Kim, Dayoung Gu, Hyunsoo Kang, Katherine E. Badior, Tong‐Shin Chang, Christian J. Kastrup, 혁진 이 · 2026 · Journal of Controlled Release
  32. Two Classes of Protein Therapeutics: Why Dose–Response Architecture Defines the Boundary of mRNA Medicines
    Sarfaraz K. Niazi · 2026 · Pharmaceutics
  33. Co-Designing mRNA Cargo and Lipid Nanoparticles across Sequence Function, Intracellular Trafficking, Biodistribution, and Manufacturabil
    Hassan Ali, Mariam Farooq, Usman Shah, Bilal Khan, Sana Malik · 2026 · Pharmacophore
  34. Lipid nanoparticle-based multi-scale systemic immune programming for cancer therapy
    Xinwen Lin, Yong Li, Xiling Shen, Bowen Li, Yue Xu · 2026 · Molecular Therapy
  35. Advances and Challenges in Nanodelivery Systems for RNA Vaccines
    Hang Li, Yubo Zhao, Jiajun Yang, Jinqiao Guo, Hao Cai, Aiping Tong · 2026 · ACS Nano
  36. Biomolecules in intrafibrillar collagen mineralization: Mechanisms, biomimetic analogs, and translational contexts
    Xi Huang, Xiaoxin Ma, Li Gao, Chuanjiang Zhao · 2026 · Colloids and Surfaces B Biointerfaces
  37. Translational Challenges and Opportunities in mRNA Cancer Vaccines
    Seong Dong Jeong, Benjamin R. Schrank, James J. Mancuso, Betty Y.S. Kim, Wen Jiang, Padmanee Sharma · 2026 · Cancer Discovery
  38. Cold-adapted RNA polymerase from Pseudomonas phage Njord improves synthesis of therapeutic mRNA
    Dillon B. Nye, Tien-Hao Chen, Jennifer L. Curcuru, Eric J. Wolf, Christa N. Molé, Vidula A. Kunte, Matthew Ryan, Lili Mitchell, Dianne S. Schwarz, Joseph M. Whipple et al. · 2026 · Proceedings of the National Academy of Sciences
  39. Next-generation CAR therapies enabled by mRNA engineering and delivery
    Qinghao Zhao, Qinqin Wen, Peizhen Pu, Caili Xu, Qinchao Hu, Zhuoran Zhou, Xianxin Hua, Xuyao Zhang · 2026 · Acta Pharmaceutica Sinica B
  40. In vitro transcription for RNA vaccines and therapeutics: a quality-by-design perspective on manufacturability
    Adithya Nair, Zoltán Kis · 2026 · Biotechnology Advances
  41. A review of mRNA vaccines and host-directed therapeutics for multidrug-resistant ESKAPE pathogens
    Emmanuel Okoro Enyi, Joy Chimuanya Nnanna · 2026 · Discover Bacteria.
  42. Small Nucleic Acid Therapeutics for Ocular Diseases: Progress, Challenges, and Future Perspectives
    Qi Guo, Lushu Chen, Ziyan Wu, Qiuyang Zhang, Jinsong Xue, Huiying Zhang · 2026 · Pharmaceutics
  43. Artificial Intelligence in RNA Research: From Molecular Design to Translational Analytics and Quality Control
    Viktoria Enkmann, Natalija Rajicic · 2026 · AI Chemistry
  44. RNA vaccines in motion: A multidisciplinary exploration of design, delivery, and deployment
    Qamar Abuhassan, Ahmed Aldulaimi, O. S. Waleed, Subbulakshmi Ganesan, V. Kavitha, Laxmidhar Maharana, Renu Sharma‎, Mutabar Latipova, Nazira Madatova, Doniyor Jumanazarov et al. · 2026 · Bioimpacts
  45. dsRADAR: Imaging and Detecting Cellular dsRNA by Repurposing RNA‐Binding Proteins
    Weina Cheng, Tyson D. Todd, Alexandria L. Quillin, Harshad Ingle, Angela M. Halstead, Megan T. Baldridge, José B. Sáenz, Jennifer M. Heemstra · 2026 · Angewandte Chemie International Edition
  46. dsRADAR: Imaging and Detecting Cellular dsRNA by Repurposing RNA‐Binding Proteins
    Weina Cheng, Tyson D. Todd, Alexandria L. Quillin, Harshad Ingle, Angela M. Halstead, Megan T. Baldridge, José B. Sáenz, Jennifer M. Heemstra · 2026 · Angewandte Chemie
  47. Bioengineering strategies for improving the immunogenicity of mRNA vaccines
    Hong Wang, Ran Zhuo, Junjun Wu, Songying Ouyang · 2026 · Signal Transduction and Targeted Therapy
  48. Anatomically Accessible Local mRNA Therapeutics: From Anatomical Access to Disease‐Focused Applications
    Yashi Wang, Ruoyi Gan, Wei Chen · 2026 · Advanced Materials
  49. Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy
    Gabriel Serra-Mir, Elena Haro-Martínez, Sandra Blasco-Benito, Chiara Cannatá, José Ángel Palomeque, Anna López‐Plana, María Sanz‐Flores, Marc Sabartés, Cristina Fornaguera, Toni Celià-Terrassa · 2026 · Molecular Oncology
  50. Toward a lab-in-the-loop AI platform for RNA therapeutics
    Gen Li, Bowen Li · 2026 · Cambridge Materials Health
  51. Ab Responses to HA mRNA
    Ted Ross · 2025 · ImmPort
  52. Protective activity of mRNA vaccines
    Florian Krammer · 2024 · ImmPort
  53. Immunological Basis of Vaccine Adjuvants: From Licensed Platforms to Next-Generation Design
    Sae‐Hae Kim, Doo‐Jin Kim, Yong‐Suk Jang · 2026 · Immune Network